Bio-Vascular suffers Peri-Strips set-back:
This article was originally published in Clinica
Executive Summary
Medicare reimbursement for Bio-Vascular's Peri-Strips has ceased pending an evaluation of the product's safety and efficacy by the technical assessment committee of the Health Care Financing Administration. Peri-Strips is used in lung volume reduction surgery (LVR), generating some 40% of the company's turnover. Surgeons are asked to submit LVR results by February 13th. It is expected that data on several hundred cases will be submitted. A decision by the committee is not expected before mid-April at the earliest, says Bio-Vascular's CEO John Karcanes.